載入中
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
前收盤價
US$96.96
+US$4.90 · +5.32%
盤中時間採用ET。市場資料可能有所延遲。
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
日內區間
目前US$96.96
52週區間
目前US$96.96
盤中時間採用ET。市場資料可能有所延遲。
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
日內區間
目前US$96.96
52週區間
目前US$96.96
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 27.57億 EUR | 27.51億 EUR | 38.19億 EUR | 173.11億 EUR | 189.77億 EUR |
| 銷貨成本 | 6.16億 EUR | 5.41億 EUR | 6億 EUR | 29.95億 EUR | 29.12億 EUR |
| 毛利 | 21.4億 EUR | 22.1億 EUR | 32.19億 EUR | 143.16億 EUR | 160.65億 EUR |
| 研究與開發 | 20.22億 EUR | 22.54億 EUR | 17.83億 EUR | 15.37億 EUR | 9.49億 EUR |
| 銷售、一般及管理費用 | 6.98億 EUR | 5.99億 EUR | 5.58億 EUR | 5.41億 EUR | 3.27億 EUR |
| 營業費用 | 27.64億 EUR | 35.24億 EUR | 25.29億 EUR | 16.73億 EUR | 7.81億 EUR |
| 利息收入 | 2.52億 EUR | — | 3.51億 EUR | 4736.7萬 EUR | 156.37萬 EUR |
| 利息支出 | 1363.96萬 EUR | 1316.18萬 EUR | 776.1萬 EUR | 1582.15萬 EUR | 562.93萬 EUR |
| 折舊和攤銷 | 3.68億 EUR | 2.98億 EUR | 1.83億 EUR | 1.23億 EUR | 7520萬 EUR |
| 營業利益 | −6.24億 EUR | −13.14億 EUR | 6.9億 EUR | 126.43億 EUR | 152.84億 EUR |
| 淨利 | −10.91億 EUR | −6.65億 EUR | 9.3億 EUR | 94.34億 EUR | 102.93億 EUR |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$121
上漲空間 24.79%報告持有此股票曝險的交易所交易基金。
First Trust NYSE Arca Biotechnology Index FundFBT9594.97萬3.32%28.91億 USD0.55%US$265.4+2.00%
iShares Biotechnology ETFIBB6829.15萬0.65%108.2億 USD0.44%US$206.49+3.00%
Schwab Fundamental International Large Company Index ETFFNDF1497.15萬0.06%253.2億 USD0.25%US$53.61+0.46%
iShares Genomics Immunology and Healthcare ETFIDNA980.75萬3.07%3.2億 USD0.47%US$42.17+4.33%
State Street SPDR Portfolio Developed World ex-US ETFSPDW903.55萬0.02%404.62億 USD0.03%US$49.98+0.64%
VanEck Biotech ETFBBH732.43萬1.55%4.85億 USD0.35%US$240.47+2.75%
JPMorgan BetaBuilders Europe ETFBBEU708.06萬0.08%88.29億 USD0.09%US$75.02+0.68%
Invesco NASDAQ Next Gen 100 ETFQQQJ666.64萬0.56%12億 USD0.15%US$44.96+1.12%First Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBSchwab Fundamental International Large Company Index ETFFNDFiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR Portfolio Developed World ex-US ETFSPDWVanEck Biotech ETFBBHJPMorgan BetaBuilders Europe ETFBBEUInvesco NASDAQ Next Gen 100 ETFQQQJAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
